These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 16012178)
1. Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma. Antonioli E; Nozzoli C; Gianfaldoni G; Mannelli F; Rossi S; Betti S; Bernardeschi P; Fiorentini G; Bosi A Ann Oncol; 2005 Nov; 16(11):1849-50. PubMed ID: 16012178 [No Abstract] [Full Text] [Related]
2. Pulmonary hypertension and thalidomide therapy in multiple myeloma. Hattori Y; Shimoda M; Okamoto S; Satoh T; Kakimoto T; Ikeda Y Br J Haematol; 2005 Mar; 128(6):885-7; author reply 887-8. PubMed ID: 15755296 [No Abstract] [Full Text] [Related]
3. Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study. Lafaras C; Mandala E; Verrou E; Platogiannis D; Barbetakis N; Bischiniotis T; Zervas K Ann Oncol; 2008 Oct; 19(10):1765-9. PubMed ID: 18480066 [TBL] [Abstract][Full Text] [Related]
4. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma. Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605 [TBL] [Abstract][Full Text] [Related]
5. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK Leuk Lymphoma; 2003 Jul; 44(7):1147-9. PubMed ID: 12916866 [TBL] [Abstract][Full Text] [Related]
6. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience. Sriskandarajah P; Pawlyn C; Mohammed K; Dearden CE; Davies FE; Morgan GJ; Boyd KD; Kaiser MF Leuk Lymphoma; 2017 Feb; 58(2):494-497. PubMed ID: 27439571 [No Abstract] [Full Text] [Related]
7. Reversible dementia due to thalidomide therapy for multiple myeloma. Morgan AE; Smith WK; Levenson JL N Engl J Med; 2003 May; 348(18):1821-2. PubMed ID: 12724497 [No Abstract] [Full Text] [Related]
8. [Thalidomide for the treatment of refractory multiple myeloma]. Kakimoto T; Hattori Y; Okamoto S Rinsho Ketsueki; 2002 May; 43(5):345-8. PubMed ID: 12096483 [No Abstract] [Full Text] [Related]
9. Evaluation of thrombophylic states in myeloma patients receiving thalidomide: a reasonable doubt. Santos AB; Llamas P; Román A; Prieto E; De Oña R; De Velasco JF; Tomás JF Br J Haematol; 2003 Jul; 122(1):159-60. PubMed ID: 12823358 [No Abstract] [Full Text] [Related]
10. Efficacy and safety of thalidomide in the treatment of multiple myeloma. Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865 [No Abstract] [Full Text] [Related]
12. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Rajkumar SV; Witzig TE Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136 [TBL] [Abstract][Full Text] [Related]
13. Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. Curley MJ; Hussein SA; Hassoun PM J Clin Microbiol; 2002 Jun; 40(6):2302-4. PubMed ID: 12037117 [TBL] [Abstract][Full Text] [Related]
20. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Prince HM; Schenkel B; Mileshkin L Leuk Lymphoma; 2007 Jan; 48(1):46-55. PubMed ID: 17325847 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]